Search Results 2661 – 2680 of 3242
Gastrointestinal Effects
https://clinicalinfo.hiv.gov/node/9470
Atazanavir (Reyataz, ATV)
https://clinicalinfo.hiv.gov/node/9471
Nelfinavir (Viracept, NFV)
https://clinicalinfo.hiv.gov/node/9472
Table 14. Antiretroviral Drug Use in Pregnant People With HIV: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy | Overview
https://clinicalinfo.hiv.gov/node/9473
Appendix B: Web-Based Resources for Treating and Preventing HIV
https://clinicalinfo.hiv.gov/node/9474
Dyslipidemia
https://clinicalinfo.hiv.gov/node/9475
Table 4. Common Drugs Used for Treatment of Opportunistic Infections in Children With HIV: Preparations and Major Toxicities
https://clinicalinfo.hiv.gov/node/9476
Tenofovir AF
https://clinicalinfo.hiv.gov/node/9477
Modifying Antiretroviral Regimens in Children With Sustained Virologic Suppression on Antiretroviral Therapy
https://clinicalinfo.hiv.gov/node/9478
Abacavir (Ziagen, ABC)
https://clinicalinfo.hiv.gov/node/9479
Rilpivirine
https://clinicalinfo.hiv.gov/node/9480
Figure 1. Recommended Immunization Schedule for Children with HIV Infection Aged 0 through 18 Years; United States, 2025
https://clinicalinfo.hiv.gov/node/9481
Tipranavir
https://clinicalinfo.hiv.gov/node/9482
What’s New in the Guidelines
https://clinicalinfo.hiv.gov/node/9484
Baseline Evaluation
https://clinicalinfo.hiv.gov/node/9485
Overview
https://clinicalinfo.hiv.gov/node/9487
Didanosine (Videx, ddI)
https://clinicalinfo.hiv.gov/node/9489
Toxoplasmosis
https://clinicalinfo.hiv.gov/node/9490
Special Populations: Women With HIV
https://clinicalinfo.hiv.gov/node/9491
Antiretroviral Therapy to Prevent Sexual Transmission of HIV (Treatment as Prevention)
https://clinicalinfo.hiv.gov/node/9492